Manchester Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Manchester Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-19,984	Closed	-$118K	–	542
2019 Q3	$118K	Hold	19,984	–	–	0.01%	279
2019 Q2	$240K	Hold	19,984	–	–	0.03%	220
2019 Q1	$241K	Hold	19,984	–	–	0.03%	215
2018 Q4	$336K	Hold	19,984	–	–	0.05%	167
2018 Q3	$297K	Hold	19,984	–	–	0.04%	186
2018 Q2	$336K	Hold	19,984	–	–	0.05%	169
2018 Q1	$458K	Hold	19,984	–	–	0.07%	139
2017 Q4	$517K	Hold	19,984	–	–	0.08%	128
2017 Q3	$295K	Hold	19,984	–	–	0.05%	151
2017 Q2	$279K	Hold	19,984	–	–	0.04%	162
2017 Q1	$341K	Hold	19,984	–	–	0.05%	143
2016 Q4	$206K	Buy	19,984 +5,000	+33%	+$45.7K	0.03%	175
2016 Q3	$151K	Hold	14,984	–	–	0.02%	228
2016 Q2	$168K	Hold	14,984	–	–	0.02%	215
2016 Q1	$205K	Hold	14,984	–	–	0.03%	194
2015 Q4	$284K	Hold	14,984	–	–	0.04%	178
2015 Q3	$281K	Buy	+14,984	New	+$255K	0.05%	158

Other funds holding CNCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Manchester Capital Management's CNCE Position: Q4 2019 in Review

Manchester Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2019, closing a stake of 19,984 shares — an estimated $118K sold.

Manchester Capital Management first reported a position in CNCE in Q3 2015 and held it in 17 quarters. The position peaked at $517K in Q4 2017. 77 funds tracked by Wall St. Rank hold CNCE as of Q4 2019.

Manchester Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
Manchester Capital Management sold 19,984 Concert Pharmaceuticals, Inc. shares in Q4 2019, an estimated $118K.
Manchester Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q3 2015 and held it in 17 quarters.
Manchester Capital Management's Concert Pharmaceuticals, Inc. position peaked at $517K in Q4 2017.
77 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2019.

Based on Manchester Capital Management's 13F filing for Q4 2019, filed 10 Feb 2020.